Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

10.53 -0.08 (-0.75%)
Streaming Delayed Price Updated: 1:23 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure 
From Replimune, Inc.
Via GlobeNewswire
What Is Driving Replimune Stock’s 98% Surge Today? ↗
Via Stocktwits
News headline image
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
News headline image
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
The Best AI for Picking Stocks, Ranked by Performance ↗
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Why Replimune Stock Was Soaring Today ↗
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks. 
Via The Motley Fool
News headline image
These stocks are moving in today's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are the most active in today's session ↗
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today ↗
Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory update. 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
These stocks are moving in today's pre-market session ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
From Replimune, Inc.
Via GlobeNewswire
News headline image
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Levi & Korsinsky Notifies Shareholders of Replimune Group, Inc. (REPL) of a Class Action Lawsuit and an Upcoming Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Levi &amp; Korsinsky Notifies Shareholders of Replimune Group, Inc. (REPL) of a Class Action Lawsuit and an Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Why Replimune Stock Was Tumbling Again Today ↗
The biotech's recent meeting with FDA officials continued to resonate. 
Via The Motley Fool
News headline image
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.